Liminatus Pharma, Inc.

LIMN

Latest QuantConomy context for LIMN: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

asset

Primary venue

NASDAQ

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for LIMN. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for LIMN

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
corporate event material agreement	bullish	95	Jul 6, 01:15 PM	LIMN filed 8-K: Material Definitive Agreement, Acquisition or Disposition, Unregistered Sales of Equity - 3 material events - [very strong bullish signal]
fundamental net income change	very bullish	76	May 15, 12:00 AM	LIMN (Q1 2026, net income): grew 89.0% (-$10.21M → -$1.12M). [sequential period basis, very bullish signal]
fundamental operating income change	very bullish	76	May 15, 12:00 AM	LIMN (Q1 2026, operating income): grew 62.9% (-$2.97M → -$1.10M). [sequential period basis, very bullish signal]

FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.

Market	Exchange	Source	Asset record
LIMN	NASDAQ	fmp	Liminatus Pharma, Inc. Class A Common Stock
LIMN	NASDAQ	alpaca	Liminatus Pharma, Inc. Class A Common Stock
LIMN	NASDAQ	alphavantage	Liminatus Pharma Inc

Buys, last 90d

Sells, last 90d

Rows

Date	Insider	Role	Type	Shares	Price	Value	Filing
Jun 24, 2026	Valetudo Therapeutics LLC	Insider	other	4,373,603	—	—	4 on EDGAR
—	Ewon Comfortech Co., Ltd.	Insider	—	—	—	—	3 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.